Abstracts

Poster Presentation Dates

All odd numbered posters will be presented on Friday, November 8, 2019, while even numbered posters will be presented on Saturday, November 9, 2019.

Posters will be on display from 7 a.m. - 8 p.m., with the presenting authors required to be at their posters during lunch (12:30 - 2 p.m. on Friday, Nov. 8, and 12:35 - 2:05 p.m. on Saturday, Nov. 9) and also during the poster reception (6:30 - 8p.m. on Friday, Nov. 8, and 7 - 8:30 p.m. on Saturday, Nov. 9).

#	Title	Authors	Category	Keywords
O62	Targeting myeloid tumors by Off-the-Shelf NK cells using an NKG2C-IL15-CD33 Trispecific Killer Engager	Emily Chiu, BA; Martin Felices; Frank Cichocki, PhD; Zachary Davis, PhD; Hongbo Wang; Katie Tuininga; Daniel Vallera; Tom Lee, PhD; Ryan Bjordahl; Dan S. Kaufman, CAMD, PhD; Karl Johan Malmberg; Bahram Valamehr; Jeffrey S. Miller, MD;	Immuno-conjugates and chimeric molecules	Adoptive immunotherapy; NK/NK T cell; Targeted therapy
P693	Cooperative targeting of immunotherapy-resistant melanoma and lung cancer models by an AXL-targeting antibody-drug conjugate and immune checkpoint blockade	Julia Boshuizen, MD; Nora Pencheva; Oscar Krijgsman, PhD; Maarten Janmaat; Patricia Garrido Castro; Elke Gresnigt-Van den Heuvel; Andreas Lingnau; Maria Jure-Kunkel; Daniel Peeper, PhD;	Immuno-conjugates and chimeric molecules	Adoptive immunotherapy; Antibody; Checkpoint blockade; T cell; Tumor evasion
P694	Engineering extracellular matrix-binding checkpoint inhibitor antibodies to achieve localized cancer therapy	Jun Ishihara, PhD; Ako Ishihara; John Michael Williford; Jeffrey Hubbell;	Immuno-conjugates and chimeric molecules	Antibody; Autoimmunity; Checkpoint blockade; Immune toxicity; Targeted therapy
P695	Tumor targeting of a STING agonist with an antibody-drug conjugate elicits potent anti-tumor immune responses	Naniye Malli Cetinbas, PhD; Kalli C. Catcott, PhD; Kenneth Avocetien; Keith Bentley, PhD; Tyler Carter, PhD; Chen-Ni Chin, PhD; Susan Clardy, PhD; Timothy Eitas, PhD; Brian Jones, PhD; Eoin Kelleher; Rebecca Mosher, MD; Mark Nazzaro; Barrett Nehilla, PhD; Marina Protopopova, PhD; Pamela Shaw; Kelly Slocum; LiuLiang Qin; Josh Thomas, PhD; Liping Yang; Dorin Toader, PhD; Marc Damelin, PhD; Jeremy Duvall, PhD; Raghida Bukhalid, PhD; Timothy Lowinger, PhD;	Immuno-conjugates and chimeric molecules	Antigen presenting cells; Chemokine; Cytokine; Dendritic cell; Monocyte/Macrophage; Myeloid cells; MDSC; Solid tumors; Targeted therapy
P696	Efficacy Studies of a Novel Multi-targeted Systemic Therapy (αPD-L1/ODN1826) and Deep-Immune Profiling of Metastatic Murine Mammary Adenocarcinoma in Syngeneic Immunocompetent Models	Alan L. Epstein, MD, PhD; Alison Smith, MDPhD candidate;	Immuno-conjugates and chimeric molecules	Antibody; Antigen presenting cells; Checkpoint blockade; Immune adjuvant; Immune monitoring; Immune suppression; Solid tumors; Targeted therapy; TLR; Tumor antigens
P697	Pre-clinical characterization of the mechanism of action of a CD25-targeted pyrrolobenzodiazepine dimer-based antibody-drug conjugate targeting regulatory T cells in solid cancers	Francesca Zammarchi, PhD; Simon Chivers; Patrick H. van Berkel, Ph.D; Francesca Zammarchi, PhD;	Immuno-conjugates and chimeric molecules	Antibody; Checkpoint blockade; Chemotherapy; Clinical trial; Immune suppression; Regulatory T cell (Treg cell); Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment
P698	Chimeric protein MICA-G129R Bridges Breast Cancer Cells and Natural Killer Cells	Hui Ding, PhD candidate; Yanzhang Wei;	Immuno-conjugates and chimeric molecules	Costimulation; NK/NK T cell; Solid tumors; Targeted therapy
P699	DSP107—a first in class, bifunctional fusion protein targeting both innate and adaptive immunity	Adam Foley-Comer, MD; Shirley Greenwald; Ewa Cendrowicz; Rinat Tabakman; Shira Amsili; Alexandra Aronin; Liat Ben-Gigi-Tamir; Elina Zorde-Khvalevsky; Yosi Gozlan; Michal Dranitzki-Elhalel; Ayelet Chajut; Amnon Peled, PhD; Edwin Bremer;	Immuno-conjugates and chimeric molecules	Costimulation; Monocyte/Macrophage; Myeloid cells; T cell; Targeted therapy; Tumor microenvironment
P700	Combining CD27 costimulation and PD-1 blockade into a bispecific antibody improves T cell activation and anti-tumor activity over combination of individual antibodies	Laura Vitale, BS; Lawrence Thomas, PhD; Thomas O'Neill, BA; Jenifer Widger, BA; Laura Mills-Chen; Andrea Crocker, BS; Colleen Patterson; Anna Wasiuk; Eric Forsberg; James Boyer; Crystal Sisson; Jeffrey Weidlick, BS; Shannon Renn-Bingham; Ioannis Papayannopoulos; Russ Hammond; Joel Goldstein, PhD; Henry C. Marsh, Jr.; Li-Zhen He, MD; Michael Yellin, MD; Tibor Keler, PhD;	Immuno-conjugates and chimeric molecules	Antibody; Checkpoint blockade; Coinhibition; Costimulation; T cell
P701	A next generation bispecific antibody platform for effective tumor cell killing with minimal cytokine release	Udaya Rangaswamy, PhD; Harbani K Malik-Chaudhry, PhD; Udaya Rangaswamy, PhD; Brian Avanzino, PhD; Aarti Balasubramani; Andrew Boudreau, BA; Benjamin Buelow; Kevin Dang, BA; Laura Davison, PhD; Kathrine Harris; Sharon Hartstein; Brett Jorgensen, BA; Hannes Kehm; Yuping Li; Kyle Lorentsen, PhD; Harish Medlari; Duy Pham, BA; Kirthana Prabhakar; Ute Schellenberger, PhD; Harshad Ugamraj, BA; Nathan Trinklein, PhD; Roland Buelow, PhD; Suhasini Iyer, PhD;	Immuno-conjugates and chimeric molecules	Antibody; Leukemia/Lymphoma; T cell
P702	Informing rational immunotherapy combinations for enhancing therapeutic activity of Bi-Specific T cell Engager (BiTE®) antibody constructs in solid tumors	Deepali V. Sawant, PhD; Brian Belmontes; Famke Aeffner; Olivier Nolan-Stevaux; Jackson Egen; Jason DeVoss, PhD;	Immuno-conjugates and chimeric molecules	Antibody; Solid tumors; T cell; Tumor antigens; Tumor microenvironment
P703	Co-stimulation of OX40 or LTβR Reprograms Exhausted Lymphocytes to Acquire an Effector Phenotype in the Setting of Combined TIGIT and Checkpoint Blockade	George J. Fromm, Jr., PhD; Suresh De Silva, PhD; Arpita Patel, BA; Kyung Jin Yoo; Kellsey Johannes, BS; Kaiwen Huang; Taylor H. Schreiber, MD, PhD;	Immuno-conjugates and chimeric molecules	Checkpoint blockade; Costimulation; T cell
P704	An Fc Effector Enhanced EGFR/cMet Bispecific Antibody (JNJ-61186372), mediates EGFR/cMet Downmodulation and Therapeutic Efficacy Through Monocyte and Macrophage Trogocytosis	Smruthi Vijayaraghavan, PhD; Lorriane Lipfert; Kristen Chevalier; Barbara Bushey, BS; Benjamin Henley; Ryan Lenhart; Jocelyn Sendecki, MS; Marilda Beqiri; Hillary Millar, MS; Kathryn Packman, PhD; Matthew V. Lorenzi, PhD; Sylvie Laquerre; Sheri Moores, PhD;	Immuno-conjugates and chimeric molecules	Antibody; Chemokine; Monocyte/Macrophage; Myeloid cells; Solid tumors; Targeted therapy; Tumor antigens
P705	A chimeric adenoviral vector overcomes pre-existing adenoviral immunity to elicit antitumor immunity to the colorectal cancer antigen GUCY2C	Jagmohan Singh; John Flickinger; Robert carlson; Trevor Baybutt; Elinor Leong; Ellen Caparosa; Jamin Roh; Amanda Pattison; Jeffrey Rappaport; Joshua Barton; Tingting Yang; Scott A. Waldman; Adam E. Snook, PhD;	Immuno-conjugates and chimeric molecules	Solid tumors; Targeted therapy; Vaccine
P706	A TCR-CD3 bispecific fusion protein mediates increased presentation of peptide-HLA which associates with improved T cell activation and tumour cell killing	Duncan M. Gascoyne, PhD; David Depoil, Ph D; Karolina A. Rygiel; Nathaniel Davies, Ph D; Cheryl McAlpine, MSN; Rupert Kenefeck;	Immuno-conjugates and chimeric molecules	Antigen presenting cells; Cytokine; Gene expression; Inflammation; Solid tumors; T cell; Tumor antigens; Tumor evasion
P707	Matrix-binding IL-12 enhances tumor inflammation and drives complete remission in established cold murine tumors	Aslan Mansurov, BChen; Jeffrey Hubbell; Jun Ishihara, PhD;	Immuno-conjugates and chimeric molecules	Cytokine; Immune toxicity; Solid tumors; Targeted therapy; Tumor stroma